Bradykinin Symposium 2024

Sep 5 - Sep 6, 2024

  • Title: Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
    Presenter: Jolanta Skarbaliene, Ph.D.
    Format: Oral Presentation, Session II
    Date, time: Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
  • Title: Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL
    Presenter: Markus Magerl, M.D.
    Format: Oral Presentation, Session VII
    Date, time: Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results
    Presenter: Emel Aygören-Pürsün, M.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis
    Presenter: Marc A. Riedl, M.D., M.S.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Clinical Trials Conformity with AURORA COS: a systematic literature review
    Presenter: Remy Petersen, M.D., Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant
    Presenter: Nieves Crespo, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: The bradykinin challenge model translates across rat, monkey and human
    Presenter: Juan Bravo, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat
    Presenter: Anne Lesage, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: A novel kinin biomarker assay for characterization of bradykinin-mediated disorders
    Presenter: Evangelia Pardali, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
  • Title: A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders 
    Presenter: Evangelia Pardali, Ph.D.
    Format: Poster Presentation
    Date, time: Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

Supporting Materials

Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat 429 KB
Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL 337.3 KB
Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis 183.8 KB
Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results 622 KB
Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results 239.2 KB
Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis 186.3 KB
Clinical Trials Conformity with AURORA COS: a systematic literature review 156 KB
Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant 765.8 KB
The bradykinin challenge model translates across rat, monkey and human 1.5 MB
Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat 752.5 KB
A novel kinin biomarker assay for characterization of bradykinin-mediated disorders 905 KB
A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders 865.2 KB